A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Safety and Efficacy of EMB 001 in Subjects With Moderate-to-Severe Cocaine Use Disorder
Sponsor: Embera NeuroTherapeutics, Inc.
Listed as NCT04501874, this PHASE2 trial focuses on Cocaine Use Disorder and remains completed. Sponsored by Embera NeuroTherapeutics, Inc., it has been updated 8 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE2
Status: Unknown Status → Completed
-
Feb 2023 — Sep 2023 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Feb 2021 — Feb 2023 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Dec 2020 [monthly]
Recruiting PHASE2
First recorded
Jul 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Embera NeuroTherapeutics, Inc.
- National Institute on Drug Abuse (NIDA)
For direct contact, visit the study record on ClinicalTrials.gov .